Print this page
-
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma.
Protocol: 012320Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-Cell Malignancies.
Protocol: 012321Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma.
Protocol: 012404Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma.
Protocol: 012407Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease. (INCA34176-357)
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Protocol: 012502Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.
Protocol: 012503Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults.
Protocol: 022101Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Lymphoid Leukemia -
Leukemia Inhibitory Factor Levels after Allogeneic Transplantation.
Protocol: 022104Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-Like Tyrosine Kinase Mutation (FLT3 mut+): The FRIDA Study.
Protocol: 022301Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia